Oncology – Page 2

Nationwide Multimodal Prehabilitation Significantly Reduces Complications After Colorectal Cancer Surgery

By MedXY 07/13/2026

A nationwide cohort study demonstrated that implementing a comprehensive multimodal prehabilitation program in colorectal cancer surgery patients lowers postoperative complications and shortens hospital stay across age and health status groups.

news OB/GYN & Women’s Health Oncology

Assessing Readability of Gynecologic Cancer Patient Education Materials: Bridging the Communication Gap

By MedXY 07/13/2026

This study evaluates the reading levels of gynecologic cancer educational materials from major cancer centers and nonprofits, revealing most exceed recommended standards, potentially limiting patient comprehension and informed decision-making.

Gastroenterology news Oncology

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY 07/12/2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

news Oncology Respiratory

Optimizing Smoking Cessation Interventions in Lung Cancer Screening: Insights from the CASTL Trial

By MedXY 07/11/2026

The CASTL trial evaluated efficient combinations of tobacco cessation interventions for smokers undergoing lung cancer screening, identifying loss-framed messaging with nicotine replacement therapy as the most cost-effective strategy.

news Oncology Otorhinolaryngology

Advancing Early Detection of Nasopharyngeal Carcinoma: Evaluating the Novel Anti-BNLF2b Antibody Test

By MedXY 07/11/2026

This article critically appraises a multicenter study validating the Anti-BNLF2b antibody (P85-Ab) assay, highlighting its superior sensitivity and specificity for early nasopharyngeal carcinoma detection compared to established EBV-based biomarkers.

Clinical Updates General Surgery news Oncology

Single-Encounter Augmented Reality-Guided Localization Enhances Early-Stage Lung Cancer Resection: Review of a Pivotal Randomized Clinical Trial

By MedXY 07/11/2026

This review synthesizes evidence on AR-guided single-encounter localization for early-stage lung cancer, highlighting its noninferiority to CT-guided methods with benefits in patient comfort, radiation reduction, and procedural efficiency.

news Oncology Pediatrics

Immature Ovarian Teratomas with Microscopic Yolk Sac Tumor in Children and Adolescents: Insights from a Multicenter Study

By MedXY 07/11/2026

A comprehensive multicenter study reveals that ovarian immature teratomas with microscopic yolk sac tumor foci in pediatric patients have favorable outcomes, showing no increased recurrence risk despite higher tumor grade and stage.

news Oncology

Global Consensus 2026: Updated Multidisciplinary Guidance for Primary Localized Chordoma

By MedXY 07/09/2026

An accessible, clinician-oriented summary of the 2026 Global Chordoma Consensus—multidisciplinary, anatomy-stratified recommendations on diagnosis, surgery, high‑dose conformal radiotherapy, follow-up, and supportive care for localized chordoma.

Hematology-Oncology news Oncology

Decoding Resistance to Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm: The Role of TXNRD1 and TET2 Mutations

By MedXY 07/09/2026

This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.

news OB/GYN & Women’s Health Oncology

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study

By MedXY 07/08/2026

A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.

Gastroenterology news Oncology

Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma

By MedXY 07/08/2026

This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.

Clinical Updates Gastroenterology news Oncology Pathology & Lab Medicine

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients

By MedXY 07/07/2026

Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.

news Oncology Otorhinolaryngology

Elevated Blood Manganese Linked to Increased Risk of Head and Neck Squamous Cell Carcinomas: Insights from Mendelian Randomization

By MedXY 07/05/2026

A genetic study reveals that higher blood manganese levels are significantly associated with increased risks of oral cavity and HPV-positive oropharyngeal squamous cell carcinomas, suggesting a novel biomarker and potential target for prevention strategies in head and neck cancers.

General Surgery news Oncology

Reevaluating Lumpectomy Margin Thresholds in HR-Positive DCIS: Insights from the NRG Oncology/NSABP B-35 Trial

By MedXY 07/05/2026

This study evaluates the impact of lumpectomy margin widths on local recurrence in postmenopausal women with hormone receptor-positive DCIS undergoing lumpectomy, radiation, and endocrine therapy, suggesting minimal recurrence differences below 1-2 mm margins.

news Oncology Radiology

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration

By MedXY 07/05/2026

This study demonstrates that combining clinical variables with computed tomography radiomics features improves the prediction of recurrence-free survival in high-grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy and surgery.

Gastroenterology news Oncology

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

By MedXY 07/04/2026

This study reveals that circulating tumor DNA (ctDNA) status after colorectal liver metastasis surgery predicts survival outcomes and benefits from adjuvant chemotherapy, guiding personalized treatment.

news OB/GYN & Women’s Health Oncology

Global Variations in Concurrent Hysterectomy During Risk-Reducing Surgery for BRCA1/2 Carriers: An Integrated Quantitative and Qualitative Analysis

By MedXY 07/03/2026

This study reveals significant international differences in concurrent hysterectomy rates during risk-reducing salpingo-oophorectomy among BRCA1/2 variant carriers and explores underlying factors influencing surgical decisions across regions.

news Oncology Respiratory

Symptom Prevalence in Lung Cancer Screening: Insights from the SUMMIT Study

By MedXY 07/02/2026

The SUMMIT study reveals that respiratory symptoms are common among lung cancer screening participants and associated with increased lung cancer diagnosis risk within one year, challenging conventional asymptomatic screening definitions.

news OB/GYN & Women’s Health Oncology

Laparoscopic HIPEC as Consolidation Therapy in Advanced Epithelial Ovarian Cancer: Feasibility and Impact on Quality of Life

By MedXY 07/01/2026

Laparoscopic HIPEC following upfront treatment in advanced epithelial ovarian cancer is feasible, safe, and preserves patient quality of life, offering a promising consolidation approach.

Gastroenterology news Oncology

Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized Trials

By MedXY 07/01/2026

Two large randomized trials reveal that Helicobacter pylori infection elevates colorectal cancer risk, particularly in individuals with specific bacterial virulence factors or high genetic susceptibility, and that eradication treatment may reduce this risk in selected groups.